BNR
Burning Rock Biotech Limited
NASDAQ · CNHealthcareMedical - Diagnostics & Research
$10.07+1.00%
Price as of Jul 20, 2026
BNR profitability
Burning Rock Biotech Limited profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 74.6%
- EBITDA margin
- -4.5%
- EBIT margin
- -11.4%
- Net margin
- -11.5%
- Free cash flow margin
- -7.7%
Returns
- Return on equity
- -11.5%
- Return on assets
- -7.5%
- Return on invested capital
- -10.3%
- Asset turnover
- 0.64x
Cash efficiency
- Cash from operations
- -$5.1M
- Cash per share
- $6.25
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.